• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing

Gilead Gets Some Serious Play

I wouldn't be a buyer of Gilead on the coronavirus news, I'd be a buyer because the yield and chart look pretty darn good.
By TIMOTHY COLLINS
Feb 24, 2020 | 11:50 AM EST
Stocks quotes in this article: GILD

The most common question I'm getting from friends and email is what should I buy to benefit from the coronavirus?

At first glance, it sounds a bit cold, but traders and investors constantly search for opportunities. That doesn't mean you don't care, and some even hope they are wrong. Additionally, many are searching for a quick trade, not a long-term investment. Does anyone really want to make their fortune from the death and suffering of others? We won't answer that, but let's hope it is a resounding no.

With people clamoring for trade ideas surrounding the virus, it should be no surprise there are several virtually unknown small biotechs seeing speculative pops, but when a big name like Gilead Sciences (GILD) hits the headlines, it gets some serious play. It's important to note a company with a nearly $100 billion market cap won't see the same upside as some microcap biotech, but it also won't come with the potential of turning you into a bagholder.

Gilead closed just under $70 on Friday, but opened near $74 on news that a WHO team said the company's remdesivir drug is the only one with real efficacy against coronavirus. That's enough to get many traders excited, but it's one team and not the results of a trial. There are so many variables that go into that statement which makes it impossible to draw the conclusion the drug will be effective on a large scale. Once again, we're back to speculation.

Before the news, Gilead shares were trading in a wide weekly ascending triangle with a rising support level currently at $63 and resistance at $70. The gap higher this morning now creates a new support level of $70 with highs from the second half of 2018 becoming resistance at $74. If the stock can hold higher this week, then I suspect the bullish crossovers in the the Full Stochastics and Chaikan Oscillator indicators will hold providing bulls with some momentum and volume support.

Coronavirus aside, GILD looks fantastic above $70. I wouldn't use the virus as my primary reason for acquisition, but in a rough market, this appears to be one that could hold if the virus continues to spread or benefit from a strong technical pattern if the market rallies. I like the idea it can win on two fronts. While I'd like to see more growth on the fundamental side and a better forecast for 2020, it isn't what I would call expensive and offers a 4% dividend.

I wouldn't be a buyer of Gilead on the coronavirus news, I'd be a buyer because the yield and chart look pretty darn good. This stock appears to be a solid fit for a growth and income portfolio for moderate risk and above.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Timothy Collins had no position in the securities mentioned.

TAGS: Drug Approvals | Investing | Markets | Options | Stocks | Technical Analysis | Trading | Pharmaceuticals | Stock of the Day

More from Investing

In a Week Full of Surprises, This Was the Market's Biggest

James "Rev Shark" DePorre
Feb 3, 2023 4:42 PM EST

We had the Fed's rate decision, jobs numbers, and mega-cap tech earnings land. But here's what was the wildest action.

3 High-Yield REITs for Safe Dividend Income

Bob Ciura
Feb 3, 2023 2:31 PM EST

These names have joined the ranks of the world's most elite dividend growth companies as Dividend Aristocrats and/or Dividend Kings.

The Charts Just Don't Give Much Affirmation on Affirm Ahead of Earnings

Bruce Kamich
Feb 3, 2023 1:54 PM EST

Here's the picture we see from this payment company.

I Found a Good-Looking Arrowhead in This Biotech ETF

Bruce Kamich
Feb 3, 2023 12:50 PM EST

Let's review the charts of XBI, the SPDR S&P Biotech ETF.

Holy Fed, Batman! FAANG Has a Major Toothache!

Jim Collins
Feb 3, 2023 12:23 PM EST

Here's why the markets are sounding a lot like the campy 'Batman' show -- and how to make sure you don't succumb to the market's Joker.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:58 PM EST REAL MONEY

    Sarge Guilfoyle Breaks Down the Jobs Report, Fed Policy and Stocks!

    Watch it here!
  • 11:35 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Trading an Irrational Market
  • 02:10 PM EST REAL MONEY

    Fed Rate Decision

    Fed Lifts Benchmark Rate by 25 Basis Points, Sees ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login